PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).

Authors

Maha Hussain

Maha Hussain

Northwestern University, Chicago, IL

Maha Hussain , Karim Fizazi , Fred Saad , Per Rathenborg , Neal D. Shore , Eren Demirhan , Katharina Modelska , De Phung , Andrew Krivoshik , Cora N. Sternberg

Organizations

Northwestern University, Chicago, IL, Institut Gustave Roussy, University of Paris Sud, Cancer Medicine, Villejuif, France, Centre Hospitalier de l’Université de Montréal/CRCHUM, Montreal, QC, Canada, Herlev Hospital, Herlev, Denmark, Carolina Urologic Research Center, Myrtle Beach, SC, Pfizer, Inc., San Francisco, CA, Pfizer, Inc., San Francisco, CA, US, Astellas Pharma Inc., Leiden, Netherlands, Astellas Pharma Inc., Northbrook, IL, San Camillo Forlanini Hospital, Rome, Italy

Research Funding

Pharmaceutical/Biotech Company

Background: Men with M0 CRPC and rapidly rising prostate-specific antigen (PSA) are at high risk of developing metastatic (M1) CRPC. ENZA improves overall survival (OS) and radiographic progression-free survival in men with M1 CRPC. We hypothesized that ENZA will improve metastasis-free survival (MFS) in men with M0 CRPC. Methods: Eligible men with M0 CRPC, PSA doubling time ≤ 10 mo and PSA ≥ 2 ng/mL at screening continued androgen deprivation therapy (ADT) and were randomized 2:1 to ENZA 160 mg or PBO. The primary endpoint was MFS. Secondary endpoints included time to PSA progression, time to first use of new antineoplastic therapy, OS and safety. Results: In 1401 men, ENZA significantly prolonged median MFS (36.6 mo vs 14.7 mo [P< .0001]), time to first use of new antineoplastic therapy (39.6 mo vs 17.7 mo [P< .0001]) and time to PSA progression (37.2 mo vs 3.9 mo [P< .0001]) compared to PBO (Table). In the first interim analysis of OS there was a trend in favor of ENZA (hazard ratio [HR] = 0.80; P = .1519). Median duration of treatment was 18.4 mo vs 11.1 mo for ENZA vs PBO. Adverse events (AEs) were higher with ENZA vs PBO (any grade: 87% vs 77%; grade ≥ 3: 31% vs 23%; serious: 24% vs 18%); 10% with ENZA discontinued treatment due to AE vs 8% with PBO. Conclusions: In men with M0 CRPC and rapidly rising PSA, ENZA treatment resulted in a clinically meaningful and statistically significant 71% reduction in the risk of developing M1 CRPC. AEs were consistent with the established safety profile of ENZA. Clinical trial information: NCT02003924

Baseline CharacteristicENZA + ADT
(n = 933)
PBO + ADT
(n = 468)
Age, median, y7473
PSA doubling time < 6 mo, no. (%)715 (77)361 (77)
Serum PSA, ng/mL11.110.2
Endpoint
MFS,a median (95% CI), mo36.6 (33.1-NR)14.7 (14.2-15.0)
HR (95% CI)0.29 (0.24-0.35)
P value< .0001
Time to first use of new antineoplastic
therapy,a median (95% CI), mo
39.6 (37.7-NR)17.7 (16.2-19.7)
HR (95% CI)0.21 (0.17-0.26)
P value< .0001
Time to PSA progression,a median (95% CI), mo37.2 (33.1-NR)3.9 (3.8-4.0)
HR (95% CI)0.07 (0.05-0.08)
P value< .0001
OS,b median (95% CI), moNR (NR-NR)NR (NR-NR)
HR (95% CI)0.80 (0.58-1.09)
P value.1519

aFinal analysis; binterim analysis CI, confidence interval; NR, not reached

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Clinical Trial Registration Number

NCT02003924

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 3)

DOI

10.1200/JCO.2018.36.6_suppl.3

Abstract #

3

Poster Bd #

A4

Abstract Disclosures